Optison Echocardiogram Contrast Agent Lawsuit

Send to Friend | Bookmark | Live Chat

Optison (Perflutren Protein-Type A Microspheres for Injection), an ultrasound micro-bubble contrast agent used in echocardiography has recently been linked to deaths and serious, life-threatening cardiopulmonary reactions.

If you or a loved one have experienced a side effect after having an echocardiogram, you should contact us immediately. You may be entitled to compensation and we can help.

What’s the problem?

The U.S. Food & Drug Administration (FDA) has asked the manufacturers of ultrasound micro-bubble contrast agents Optison to add a “Boxed Warning” to their products because of recent reports linking them to deaths and serious, life-threatening cardiopulmonary reactions.

Four of the 11 reported deaths were caused by cardiac arrest occurring either during infusion or within 30 minutes following the administration of the contrast agent; most of the serious but non-fatal reactions also occurred in this time frame.

The FDA requested Boxed Warning would emphasize the risk for serious, life-threatening side effects including heart attacks and other cardiopulmonary reactions in patients with unstable angina, acute myocardial infarction, respiratory failure, or recent worsening congestive heart failure.

Do I Have a Optison Lawsuit?

The Medical Device and Product Liability Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in defective medical product / device lawsuits. We are currently pursuing individual litigation nationwide and accepting new Optison cases in all 50 states.

Attention Attorneys: We do not publish prior verdict/settlements. If you are an attorney and would like to refer us a case or for us to send you a profile of prior award judgments or average referral fees, please visit the attorney referral section of our website.

= Required Field